Trazodone treatment increases plasma prolactin concentrations in depressed patients

Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. doi: 10.1097/00004850-199506000-00009.

Abstract

m-Chlorophenylpiperazine (m-CPP), which is a metabolite of trazodone, is a serotonin agonist. To examine for the possibility that m-CPP is involved in biochemical effects during treatment with the parent compound, prolactin response to trazodone treatment (150 mg at bedtime for 3 weeks) was studied in 12 depressed patients. The means +/- S.D. of plasma prolactin concentrations before treatment, 12 h, and 1, 2 and 3 weeks after initiation of treatment were 9.1 +/- 5.6, 14.7 +/- 9.1, 15.3 +/- 8.5, 13.2 +/- 7.0 and 13.0 +/- 7.0 ng/ml, respectively. The mean prolactin concentrations at 12 h (p < 0.01), 1 week (p < 0.001) and 2 weeks (p < 0.05) were significantly higher than that before treatment. The present study thus shows that trazodone treatment increases prolactin concentrations, suggesting that m-CPP is involved in biochemical effects during treatment with the parent compound.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Depressive Disorder / blood
  • Depressive Disorder / drug therapy*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Piperazines / metabolism
  • Prolactin / blood*
  • Trazodone / therapeutic use*

Substances

  • Piperazines
  • Prolactin
  • 1-(3-chlorophenyl)piperazine
  • Trazodone